A Phase I/II Clinical Study to assess safety, potency and durability of SR-02 implanted to the abdominal omentum of patients with difficult-to-control T1D

Lifesciences Magazine: Battling Diabetes! Exclusive Interview with the Glen Travers (Co-founder of Diabetology Limited), Leading Biopharma Company Pushing Boundaries

$400,000 award will support characterization and efficacy testing of preclinical SR-03 cell line as a part of IND development. Seraxis is taking meetings at the American Diabetes Association Annual Meeting in Orlando, June 21-24.

Innovative pro-drug delivers superior efficacy with improved drug-like properties and safety profile

GMP-compliant manufacturing puts SR-02 on track to be industry’s second clinical-stage stem cell derived pancreatic islet transplant program.

The third-party auditor’s FDA six-system approach yielded no critical nor major observations of Seraxis’ quality system for the production of GMP-grade organs from pancreas-derived stem cells.

Dr. William Rust, CEO, will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 on Monday, January 8 at 10:30 a.m. PST at Biotech Showcase in San Francisco.

Ananda Professional unveils GluNOzym™ + Reducose®, a revolutionary product designed to redefine blood sugar management and support healthy weight. Combining innovative ingredients, including clinically researched Reducose®, this groundbreaking single-gummy solution blocks sugars and starches from turning into blood glucose. Backed by impressive clinical data, GluNOzym™ emerges as a game-changer in the wellness industry.

A recent study published in the Journal of Wound Care (UK) has shed light on a revolutionary approach to diabetic foot care that promises hope and relief for millions worldwide.

Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function.

Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled “Novel stem cell-derived islet-like clusters potently control rodent blood glycemia”.

Seraxis will be taking meetings at BIO-Europe, November 6-8, in Munich.

Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets for Treating Diabetes”, will be delivered in the session entitled "Transplantation of Islet and Stem Cells Today and Tomorrow".

Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date

New Service Helps Save Money, Improve Health for Population of 151 Million

Kentucky-based startup will provide informed health decisions surrounding diabetes and prediabetes diagnoses

Unannounced Meal Management Efficacy Key to a Better Quality of Life for People with Diabetes

The SweetLeaf and American Diabetes Association partnership will promote healthy alternatives to sugar, drive awareness of diabetes risk and management and help diabetics take action to improve their health.

Co-developing a dedicated smartphone app that controls the AID system. European market should be first to launch. Expanding product lineups and business.

This Donation will Assist the State's Fight Against COVID-19

Confirmed Improvement in Time in Range +18.4 Percentage Points; Reduction of Time Spent in Hypoglycemia to Only 0.9%

PolarSeal Tapes and Conversions, a leading contract medical device manufacturer and adhesive converter, will now provide cost-effective and bespoke solutions for US' wearable medical device market.

Practical cure of type 1 diabetes, alopecia areata, and other autoimmune diseases by the Stem Cell Educator therapy

Helmsley Charitable Trust Supports Effort to Strengthen Clinician Accountability

Happy Bob App offers Dexcom CGM users and their caregivers more ways to interact with their glucose data, including a real-time iOS widget, Apple Watch app, groups, gamification, and humorous personalized messages.

Paper Composed Collaboratively by Diabetes Expert Panel, Funded by Helmsley Charitable Trust

ExpressionMed, who has been making designed medical tapes for over six years, is launching its biggest awareness campaign yet.

After the success in Europe, the award-winning SNAQ App is now available for people living with diabetes in the United States. The app supports seamless integration with many popular glucose sensors and diabetes apps. Alongside this launch, Anton Kittelberger, Dr. David Kerr and John Sjolund are newly joining the Advisory Board of SNAQ.

What started as an idea to build confidence for a close friend with diabetes has grown over the past five years into a multi-million-dollar company with a mission to improve the quality of life for CGM wearers.

Humana and PQS to expand EQuIPP® platform-based program regionally in 2021, enabling more pharmacists to provide enhanced support to patients in managing their diabetes goals

Enables Dexcom users to sync their glucose values onto a single, unified dashboard and share with any healthcare professional.

New service offerings include: In-Home COVID testing, diabetes monitoring, and e-learning programs and are among the many exciting initiatives in place for 2021.

Congresswoman Donna Shalala to join leading scientists, developers, regulators, and policy/business decision-makers who are seeking to accelerate translation of major scientific discoveries into products that slow the aging process and onset of major chronic diseases.

Modern Heart and Vascular Institute is expanding to Cleveland, Texas. They will be opening a full-time clinic at 212 N College Ave. Suite B, Cleveland, TX 77327.

Designed to Deliver the Best Injection Experience

Investment will be used to advance its novel vapor-based ablation system to treat precancerous conditions and metabolic disease such as type 2 diabetes in the gastrointestinal (GI) tract.